Lifeboat Foundation

Glad Intel is moving this dial on their side as I have said for over a year they must do this to remain relevant. I would also encourage them to enter into a large 3D/4D printer partnership to develop a high speed printer that can print diamoide particles as they will need this bi-product to ensure stability in their chips and any other QC data storage and transfer processing. I do say they will need a group focused on Quantum Bio R&D as we begin to progress more of a integrated tech-bio system approach.

Intel realizes there will be a post-Moore’s Law era and is already investing in technologies to drive computing beyond today’s PCs and servers.

The chipmaker is “investing heavily” in quantum and neuromorphic computing, said Brian Krzanich, CEO of Intel, during a question-and-answer session at the company’s investor day on Thursday.

Continue reading “Intel researches tech to prepare for a future beyond today’s PCs” »

MIT spinout Manus Biosynthesis engineers microbes to produce rare and expensive ingredients for noncaloric beverages, perfumes, toothpastes, detergents, pesticides, and therapeutics. Spun out of the MIT Department of Chemical Engineering, Manus technologies could lead to new discoveries in drug development and product ingredients.

Looks like an interesting book for my Quantum Bio friends.

Quantum mechanics provides the most accurate microscopic description of the world around us, yet the interface between quantum mechanics and biology is only now being explored. This book uses a combination of experiment and theory to examine areas of biology believed to be strongly influenced by manifestly quantum phenomena. Covering subjects ranging from coherent energy transfer in photosynthetic light harvesting to spin coherence in the avian compass and the problem of molecular recognition in olfaction, the book is ideal for advanced undergraduate and graduate students in physics, biology a…

Someone invented an anti-choking device as an alternative to the Heimlich maneuver.

The world’s top AI researchers met to consider the threats posed by their research. The global economy could be the first casualty.

The plan could dramatically shift the mission of the space agency, prioritizing low-Earth orbit activity over distant exploration.

Let’s debate whether ageing is a disease *after* the diseases of old age are eliminated, shall we?

Whether or not ageing ought to be considered a disease is still matter of controversy, both among experts and laypeople. Particularly, the latter tend to turn up their noses at the thought of ageing being pathological and not ‘normal’, especially if they’re outside the life-extension/rejuvenation community. Clearly, they ignore the fact that ‘normal’ and ‘pathological’ aren’t mutually exclusive at all. It’s perfectly normal to suffer from hear loss in old age; notwithstanding, it is out of the question that hear loss is a pathology and we have developed several ways to make up for it. It presently can’t be cured, because like all age-related diseases, it can only get worse as long as the age-related damage that causes it keeps accumulating.

In my humble opinion of quasi-layperson (I’m nowhere near being an expert, but I do think I know about ageing more than your average Joe), whether or not ageing is a disease is merely a matter of semantics, depending largely on what we want to label as ‘ageing’—not to mention how we define ‘disease’.

If we say that ‘ageing’ is the set of age-related pathologies that affect a given person, then ageing isn’t a disease any more than a box of crayons is itself a crayon. Nonetheless, if you have a box of crayons then you have a bunch of crayons; if you have ageing as we defined it, then you have a bunch of diseases, and the grand total of your ailments doesn’t change whether you consider ageing as a disease as well or not. Quite frankly, I’d pick the box of crayons over ageing any time.

Continue reading “Health before semantics” »

Some small write-ups out today on the NY Times piece coverig transhumanism, including in The Paris Review, a well known literary publication for writing folks out there: https://www.theparisreview.org/blog/2017/02/09/touch-someone…ther-news/ &

http://transhumanist-party.org/2017/02/10/nyt-magazine-zoltan/ &

http://www.themillions.com/2017/02/dying-totally-mainstream.html

Continue reading “Nan Goldin: Photography Is ‘a Chance to Touch Someone with a Camera’” »

Brogan BamBrogan has jumped back into the race to transform transportation. The engineer, who left Hyperloop One amid a wild legal battle last summer, has launched his own effort to build a network of tubes and pods to fling people about the planet at near-supersonic speeds. It’s called Arrivo (Italian for “arrived”), and it plans to put you—or at least your stuff—in a working hyperloop in just three years.

As CEO, BamBrogan (yes, that’s his legal name) says the new Los Angeles–based company has lined up funding and is in talks to produce hyperloop systems for a variety of clients. Without revealing where those projects are, he says he plans to start by moving cargo, a good way to prove the system works and iron out the kinks without killing anybody, all while bringing in some revenue.

BamBrogan is a respected engineer who spent years at SpaceX before cofounding Hyperloop One with venture capitalist Shervin Pishevar in 2014. In July, he and three coworkers sued the company, alleging shenanigans like breach of fiduciary duty, violating labor laws, wrongful termination, and infliction of emotional distress. Hyperloop One countersued, accusing BamBrogan et al. of an attempted mutiny. In November, the aggrieved parties reached a confidential settlement and dropped the suits, which involved details like an overpaid fiancée, drunken shouting, a nightclub bouncer, and … um … a noose.

Continue reading “The Hyperloop’s Best-Known Engineer—Brogan BamBrogan—Is Back in the Race With His Own Company” »